Enfusion (ENFN) to Release Earnings on Tuesday

Enfusion (NYSE:ENFN) is anticipated to post its quarterly earnings results before the market opens on Tuesday, March 11th. Analysts expect Enfusion to post earnings of $0.06 per share and revenue of $54.39 million for the quarter.

Enfusion (NYSE:ENFN) last announced its earnings results on Monday, March 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). Enfusion had a return on equity of 6.67% and a net margin of 1.70%. On average, analysts expect Enfusion to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Enfusion Stock Down 1.0 %

Shares of Enfusion stock opened at $11.36 on Tuesday. The stock has a market capitalization of $1.46 billion, a P/E ratio of 284.07, a PEG ratio of 1.85 and a beta of 0.96. The stock has a 50 day moving average price of $10.91 and a two-hundred day moving average price of $9.81. Enfusion has a 12-month low of $7.83 and a 12-month high of $11.80.

Insider Buying and Selling

In related news, CFO Bradley Herring sold 4,134 shares of the firm’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total value of $41,877.42. Following the completion of the transaction, the chief financial officer now directly owns 266,369 shares of the company’s stock, valued at $2,698,317.97. This trade represents a 1.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Oleg Movchan sold 2,771 shares of the firm’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total value of $28,070.23. Following the completion of the transaction, the chief executive officer now directly owns 526,702 shares of the company’s stock, valued at approximately $5,335,491.26. This trade represents a 0.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 35,566 shares of company stock valued at $372,671 over the last ninety days. 36.44% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Piper Sandler upped their target price on Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research report on Monday, December 23rd. Stifel Nicolaus increased their price objective on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Finally, William Blair reissued a “market perform” rating on shares of Enfusion in a research report on Monday, January 13th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $11.13.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.